Filed pursuant to Rule 424(b)(3)
SEC File No. 333-275856
PROSPECTUS SUPPLEMENT NO. 2
(to Prospectus dated February 8, 2024)
1,600,000 Shares of Common Stock
1,600,000 Warrants to Purchase up to 3,200,000 Shares of Common Stock
1,600,000 Pre-Funded Warrants to purchase up to 1,600,000 Shares of Common Stock
4,800,000 Shares of Common Stock underlying Warrants and Pre-Funded Warrants
Tenax Therapeutics, Inc.
|
This prospectus supplement updates, amends and supplements the prospectus dated February 8, 2024, as amended by Prospectus Supplement No. 1 dated February 20, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-275856). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with information contained in our Current Report on Form 8-K filed with the SEC on February 23, 2024, which is set forth below.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.
Our Common Stock is listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “TENX.” The last reported closing price for our Common Stock on Nasdaq on February 23, 2024 was $3.98 per share.
|
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 19 of the Prospectus for a discussion of information that should be considered in connection with an investment in our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of the disclosures in the prospectus. Any representation to the contrary is a criminal offense.
|
The date of this prospectus supplement is February 23, 2024
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 22, 2024
Tenax Therapeutics, Inc. |
(Exact name of registrant as specified in its charter) |
Delaware |
| 001-34600 |
| 26-2593535 |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
101 Glen Lennox Drive, Suite 300
Chapel Hill, North Carolina 27517
(Address of principal executive offices) (Zip Code)
919-855-2100
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, $0.0001 par value per share | TENX | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On February 22, 2024, Tenax Therapeutics, Inc. (the “Company”) received written notification from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company had over 500,000 publicly held shares of its common stock and that as a result the Company had regained compliance with Nasdaq Listing Rule 5550(a)(4) (the “Minimum Float Requirement”) and that the matter is now closed.
As previously reported, on January 11, 2024, Nasdaq notified the Company that the Company no longer met the Minimum Float Requirement for continued inclusion on the Nasdaq Capital Market.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 23, 2024 | Tenax Therapeutics, Inc. |
| |
|
|
|
|
| By: | /s/ Christopher T. Giordano |
|
| Christopher T. Giordano |
| |
| President and Chief Executive Officer |
| |
3 |